Catherine Lai, MD, MPH, discusses strategies for optimizing outcomes in the long-term management of Acute Myeloid Leukemia (AML), particularly for patients in first remission without a transplant. She also shares perspectives on updates from the 65th ASH Annual Meeting.
Join Catherine Lai, MD, MPH in this informative OncLive News Network program as she explores strategies for optimizing outcomes in the long-term management of Acute Myeloid Leukemia (AML), with a focus on patients in first remission without a transplant. Here, she provides a brief overview of the current incidence of AML, its risk factors, and prognosis.
Expert perspectives on the role of biomarker testing in the diagnosis and management of acute myeloid leukemia.
Catherine E. Lai, MD, MPH, discusses the current standard of care in the first-line treatment of patients with AML and which factors guide therapy selection.
Insight into monitoring patients who are being treated for AML, what constitutes complete remission, and how and why it’s important to test for minimal residual disease to determine a patient’s risk for relapse.
Catherine E. Lai, MD, MPH, shares her approach to treatment after a patient with AML completes induction therapy.
A review of recent data regarding maintenance therapy for patients with AML who achieve first remission, including updates from the 2023 ASH Annual meeting.
Catherine E. Lai, MD, MPH, discusses the goals of maintenance therapy, how to manage treatment-related adverse events, and the impact of treatment on patient’s quality of life.
A discussion about how ensuring continuity of care for patients with AML on maintenance therapy with a focus on how the care team can coordinate to ensure best outcomes.
Expert perspectives on some of the challenges faced in managing the treatment of patients with AML upon first remission.
A look at emerging treatments and remaining unmet needs in the overall treatment landscape for acute myeloid leukemia.
